The TGFβ2 mRNA level was significantly decreased in the late telogen HFs in the group administered 60 mg/kg of the MWC compared to the control group; however, there was no significant difference in any of the MWC-administered groups (Figure 5G). The gene discussed is TGFB2; the disease is Hand-foot syndrome.